Replies to post #352275 on Bioelectronics Corp (BIEL)

[normal investor]

With due respect and without taking away the excitement from the longs. I am not buying into this news, my conviction is 1/10. 1 is just a benefit of doubt. My background check says that the site is an AI run one with imaginary people names in each of the article. Since I knew this news there were more than 5 articles every other day or two. I would keep my focus on the Electrome deal which is a totally on ground and fully functional work going on. Only piece of the puzzle pending is BIEL opening their mouth. 

[srinsocal]

Thanks longtrailer & Hawk, initially I had only read the isolated paragraph concerning the Voltaren ActiPatch.

Looking at the whole article gives a different perspective. This article was written by an established analyst, "By Dr. Elena Voss, Senior Pharma Market Analyst: Voltaren's evolution from Novartis/GSK joint venture legacy to Haleon's core growth driver underscores its enduring appeal in high-margin OTC markets like Switzerland's pain relief sector."

Dr. Voss does a deep dive into Haleon's Voltaren product. It sure sounds like she had a source inside of Haleon for her article.

New product R&D does not always make it onto store shelves, but I feel confident that Haleon is exploring a Voltaren ActiPatch Hybrid.